Anthem Biosciences IPO GMP Today! Why Are People Buying?
2025-07-17
Anthem Biosciences is making headlines ahead of its listing, with investors closely watching the Grey Market Premium (GMP). As of July 17, 2025, the IPO’s GMP stands between ₹144–₹154, suggesting a premium of nearly 25–27% over the issue price of ₹570.
This strong interest reflects not just listing enthusiasm but deeper investor confidence in Anthem’s growth story, market position, and financial stability. Here’s why this IPO is attracting so much attention.
Anthem Biosciences IPO GMP Today
The Grey Market Premium (GMP) is often a litmus test of an IPO’s pre-listing sentiment. For Anthem Biosciences, the current GMP indicates a possible listing price in the ₹714–₹724 range.
This valuation is driven by strong investor appetite, significant oversubscription, and anticipation of solid listing-day performance. The GMP has remained consistently strong since the IPO closed, reinforcing bullish expectations.
Read more: ASML Stock Drops 11%! Is the Company's Future at Stake?
Why Are Investors Buying Anthem Biosciences IPO?
Strong Grey Market Sentiment
- A consistently high GMP reflects strong pre-listing demand.
- Grey market trends are often early indicators of public market performance.
Exceptional Subscription Number
- The IPO was oversubscribed 67.4 times overall.
- Qualified Institutional Buyers (QIBs) showed intense interest, subscribing 192.8 times.
- Non-institutional investors and retail participation were also robust at 44.7x and 5.98x, respectively.
Strong Financial Performance
- Net profit for FY25 stood at ₹451 crore, marking a 23% YoY growth.
- Revenue reached ₹1,930 crore with a healthy EBITDA margin of 36.8%, indicating operational efficiency.
Read more: Should You Buy OPEN? Analyzing the Surging Meme Stock
Leadership in the CRDMO Sector
- Anthem is a leading Contract Research, Development, and Manufacturing Organization (CRDMO).
- It serves global biotech and pharma firms with end-to-end services from discovery to manufacturing.
Growth Prospects and Sector Tailwinds
- Ongoing expansion in fermentation capacity (to reach 182kL by mid-2026) strengthens its global delivery capabilities.
- Sector growth, global supply chain realignment, and India’s cost advantage create a strong macro backdrop.
Peer Comparison and Premium Valuation
- IPO’s P/E ratio of 70x aligns with peers like Syngene and Divi’s Labs.
- Analysts justify the premium due to Anthem’s integrated model and growth visibility.
Reputed Anchor and Institutional Investors
- Anchor book included names like Abu Dhabi Investment Authority, HDFC MF, ICICI Pru MF, Quant MF, and more.
- Such participation adds institutional credibility and retail confidence.
Regulatory Approvals
- Anthem holds approvals from USFDA, ANVISA, and other global regulators.
- This enables it to service multinational clients and reduce regulatory risks.
Rea more: HDFC Bank Share Price Analysis
Anthem Biosciences IPO Snapshot
Final Thought
Anthem Biosciences’ IPO has captured attention for all the right reasons—stellar financials, a dominant position in the CRDMO market, robust demand, and trusted institutional backing. For investors looking at biotech exposure with promising fundamentals, this IPO offers a compelling proposition.
If listing momentum holds, Anthem could set the tone for upcoming pharma and biotech IPOs in India’s capital markets.
Read more:
Ashok Leyland Share Price Crash
Should I Invest in Bitcoin or Altcoins in Q3 2025?
Eclipse is Officially Live on Bitrue, Get Rewards Up To 11,000 $ES Tokens!
Crypto Profit Calculator: How to Measure Your Gains or Losses in Crypto
FAQ
What is the GMP of Anthem Biosciences IPO today?
The GMP as of July 17, 2025, is between ₹144 and ₹154, indicating strong listing-day expectations.
Is Anthem Biosciences IPO a good investment?
Based on financials, sector position, and oversubscription, many analysts consider it a strong bet, particularly for listing gains.
What does Anthem Biosciences do?
It’s a CRDMO that offers end-to-end solutions in drug research, development, and manufacturing for global pharma clients.
Who are the key investors in Anthem Biosciences IPO?
Anchor and institutional investors include Abu Dhabi Investment Authority, HDFC Mutual Fund, and ICICI Prudential.
When will Anthem Biosciences list on the stock exchange?
The listing is expected shortly after the allotment, likely within a week of July 17, 2025.
Disclaimer: The content of this article does not constitute financial or investment advice.
